Investment
Features
FeesSafety
Academy
More
Pluang+

Class action lawsuit filed against Smartsheet over undisclosed acquisition offer during stock buybacks

Market News
14 Sep 2026
Newsfile Corp
View Source
Bearish
Class action lawsuit filed against Smartsheet over undisclosed acquisition offer during stock buybacks

A class action lawsuit has been filed against Smartsheet Inc. for allegedly repurchasing its own stock while knowing about a formal acquisition offer from Blackstone and Vista Equity Partners at prices higher than the market. The complaint claims Smartsheet failed to disclose this acquisition offer to shareholders during the buyback period from June to September 2024, potentially causing losses to sellers who were unaware of the offer. Investors who sold shares during this period are encouraged to contact the law firm Kaplan Fox & Kilsheimer LLP to learn about joining the lawsuit or becoming lead plaintiffs. The case highlights issues of transparency and fair treatment of shareholders during significant corporate transactions.

The class action lawsuit against Smartsheet Inc. provides context for technology sector trading on Pluang. For readers following Technology stocks, here is Pluang's market snapshot as of Sep 15, 2026 00:03 WIB: out of 150 priced US tech stocks, 91 rose and 58 fell. Among notable movers, Teradyne (TER) dropped 12.05% to USD 334.10, contrasting with Wix.Com (WIX) and HubSpot (HUBS), which gained 11.15% and 10.07% to USD 85.12 and USD 248.03 respectively.

More News

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...

Company Fundamentals
Neutral
15 minutes ago
Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...

Analyst Insights
Bullish
1 hour ago
Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...

Analyst Insights
Bullish
1 hour ago
Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...

Analyst Insights
Bullish
2 hours ago
$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

An investment of $10,000 in Marvell stock a decade ago has grown to approximately $206,000 today. Achieving the same growth again would require an annual earnings increase of 35%. This highlights Marvell's strong past performance and the challenge of...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App